Biodesix, Inc. - Common Stock (BDSX)

Biodesix (NASDAQ:BDSX) reported second-quarter 2026 revenue growth of 34% year over year, supported by increased diagnostic test volumes, higher average revenue per test and continued expansion of its commercial organization. Total revenue was $26.9 million for the quarter, while diagnostic testing

Biodesix (BDSX) Q1 2026 Earnings Transcript

Biodesix BDSX Q2 2025 Earnings Call Transcript

Biodesix (BDSX) Q4 2025 Earnings Call Transcript

On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025 financial results that comfortably beat both internal guidance and Wall Street estimates. The Colorado-based lung diagnostics specialist reported a

The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Let's have a look at the gap up and gap down stocks in today's session.

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

U.S. stock futures were swinging on Thursday following Wednesday's mixed moves. Futures of major benchmark indices were mixed.